View in EDS

A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma.

Saved in:
Bibliographic Details
Title: A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma.
Authors: Piperno-Neumann S; Institut Curie, Paris, France. sophie.piperno-neumann@curie.fr., Carlino MS; Blacktown and Westmead Hospitals, Sydney, NSW, Australia.; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia., Boni V; START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain., Loirat D; Institut Curie, Paris, France., Speetjens FM; Leiden University Medical Center, Leiden, The Netherlands., Park JJ; Blacktown and Westmead Hospitals, Sydney, NSW, Australia., Calvo E; START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain., Carvajal RD; Columbia University Irving Medical Center, New York, NY, USA., Nyakas M; Oslo University Hospital, Oslo, Norway., Gonzalez-Maffe J; Novartis Pharma AG, Basel, Switzerland., Zhu X; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Shirley MD; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Ramkumar T; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Fessehatsion A; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Burks HE; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Yerramilli-Rao P; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Kapiteijn E; Leiden University Medical Center, Leiden, The Netherlands.
Source: British journal of cancer [Br J Cancer] 2023 Apr; Vol. 128 (6), pp. 1040-1051. Date of Electronic Publication: 2023 Jan 09.
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 36624219
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Piperno-Neumann+S%22">Piperno-Neumann S</searchLink>; Institut Curie, Paris, France. sophie.piperno-neumann@curie.fr.<br /><searchLink fieldCode="AU" term="%22Carlino+MS%22">Carlino MS</searchLink>; Blacktown and Westmead Hospitals, Sydney, NSW, Australia.; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.<br /><searchLink fieldCode="AU" term="%22Boni+V%22">Boni V</searchLink>; START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Loirat+D%22">Loirat D</searchLink>; Institut Curie, Paris, France.<br /><searchLink fieldCode="AU" term="%22Speetjens+FM%22">Speetjens FM</searchLink>; Leiden University Medical Center, Leiden, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Park+JJ%22">Park JJ</searchLink>; Blacktown and Westmead Hospitals, Sydney, NSW, Australia.<br /><searchLink fieldCode="AU" term="%22Calvo+E%22">Calvo E</searchLink>; START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Carvajal+RD%22">Carvajal RD</searchLink>; Columbia University Irving Medical Center, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Nyakas+M%22">Nyakas M</searchLink>; Oslo University Hospital, Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Gonzalez-Maffe+J%22">Gonzalez-Maffe J</searchLink>; Novartis Pharma AG, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Zhu+X%22">Zhu X</searchLink>; Novartis Institutes for BioMedical Research, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Shirley+MD%22">Shirley MD</searchLink>; Novartis Institutes for BioMedical Research, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Ramkumar+T%22">Ramkumar T</searchLink>; Novartis Institutes for BioMedical Research, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Fessehatsion+A%22">Fessehatsion A</searchLink>; Novartis Institutes for BioMedical Research, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Burks+HE%22">Burks HE</searchLink>; Novartis Institutes for BioMedical Research, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Yerramilli-Rao+P%22">Yerramilli-Rao P</searchLink>; Novartis Institutes for BioMedical Research, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Kapiteijn+E%22">Kapiteijn E</searchLink>; Leiden University Medical Center, Leiden, The Netherlands.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220370635%22">British journal of cancer</searchLink> [Br J Cancer] 2023 Apr; Vol. 128 (6), pp. 1040-1051. <i>Date of Electronic Publication: </i>2023 Jan 09.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Publishing+Group+on+behalf+of+Cancer+Research+UK%22">Nature Publishing Group on behalf of Cancer Research UK </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>0370635 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1532-1827 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200070920%22">00070920 </searchLink><i>NLM ISO Abbreviation: </i>Br J Cancer <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36624219
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41416-022-02133-6
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1040
    Titles:
      – TitleFull: A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Piperno-Neumann S
      – PersonEntity:
          Name:
            NameFull: Carlino MS
      – PersonEntity:
          Name:
            NameFull: Boni V
      – PersonEntity:
          Name:
            NameFull: Loirat D
      – PersonEntity:
          Name:
            NameFull: Speetjens FM
      – PersonEntity:
          Name:
            NameFull: Park JJ
      – PersonEntity:
          Name:
            NameFull: Calvo E
      – PersonEntity:
          Name:
            NameFull: Carvajal RD
      – PersonEntity:
          Name:
            NameFull: Nyakas M
      – PersonEntity:
          Name:
            NameFull: Gonzalez-Maffe J
      – PersonEntity:
          Name:
            NameFull: Zhu X
      – PersonEntity:
          Name:
            NameFull: Shirley MD
      – PersonEntity:
          Name:
            NameFull: Ramkumar T
      – PersonEntity:
          Name:
            NameFull: Fessehatsion A
      – PersonEntity:
          Name:
            NameFull: Burks HE
      – PersonEntity:
          Name:
            NameFull: Yerramilli-Rao P
      – PersonEntity:
          Name:
            NameFull: Kapiteijn E
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 04
              Text: 2023 Apr
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 1532-1827
          Numbering:
            – Type: volume
              Value: 128
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: British journal of cancer
              Type: main
ResultId 1